Ong Michael M, Li Yingjoy, Lipner Shari R
Weill Cornell Medicine, New York, NY, USA.
Irvine School of Medicine, University of California, Irvine, CA, USA.
Am J Clin Dermatol. 2025 Oct 21. doi: 10.1007/s40257-025-00990-4.
Low-dose oral minoxidil has gained recognition as an off-label treatment for hair loss disorders, including androgenetic alopecia, telogen effluvium, and alopecia areata. Originally developed to treat hypertension, its hair growth-promoting effects are attributed to multiple mechanisms: primarily through direct KATP channel activation in dermal papilla cells, with additional effects from Wnt/β-catenin signaling, enhanced cysteine incorporation, and modulation of inflammatory and androgenic pathways. Clinical studies demonstrate comparable efficacy to topical minoxidil, with the added advantages of improved adherence, lower cost, and reduced application-related side effects. Common adverse effects include dose-dependent hypertrichosis (24% incidence), transient shedding (16-22%), and mild peripheral edema (2%), while serious complications, including pericardial effusion, are rare at doses used for alopecia. International Delphi consensus supports standardized dosing: 1.25 mg/day starting dose for women (range 0.625-5 mg/day) and 2.5 mg/day for men (range 1.25-5 mg/day), with lower doses recommended for adolescents and caution advised in renal/hepatic impairment. Contraindications include pericardial disease, uncontrolled hypertension, and pregnancy. While current evidence supports its safety and efficacy, further research is needed to establish long-term outcomes and optimal use in pediatric populations. With appropriate monitoring, oral minoxidil represents a promising therapeutic option in the management of hair loss disorders.
低剂量口服米诺地尔已成为一种用于治疗脱发疾病的非标签治疗方法，这些疾病包括雄激素性脱发、休止期脱发和斑秃。米诺地尔最初是开发用于治疗高血压的，其促进头发生长的作用归因于多种机制：主要是通过直接激活真皮乳头细胞中的KATP通道，此外还有Wnt/β-连环蛋白信号传导、增强半胱氨酸掺入以及调节炎症和雄激素途径的作用。临床研究表明，其疗效与局部用米诺地尔相当，还具有依从性提高、成本降低和应用相关副作用减少等额外优势。常见的不良反应包括剂量依赖性多毛症（发生率24%）、短暂性脱发（16 - 22%）和轻度外周水肿（2%），而在用于治疗脱发的剂量下，包括心包积液在内的严重并发症很少见。国际德尔菲共识支持标准化给药：女性起始剂量为1.25毫克/天（范围为0.625 - 5毫克/天），男性为2.5毫克/天（范围为1.25 - 5毫克/天），青少年建议使用较低剂量，肾功能/肝功能损害者需谨慎使用。禁忌证包括心包疾病、未控制的高血压和妊娠。虽然目前的证据支持其安全性和有效性，但仍需要进一步研究以确定长期疗效以及在儿科人群中的最佳使用方法。通过适当的监测，口服米诺地尔在脱发疾病的治疗中是一种有前景的治疗选择。
